$STXS
Stereotaxis, Inc. Stock $stxs

$stxs Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022008 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$7.657M	$6.152M	$7.037M
YoY Change	-15.92%	-32.03%	-18.39%
Cost Of Revenue	$3.090M	$1.482M	$2.113M
YoY Change	-29.32%	-41.17%	-18.94%
Gross Profit	$4.567M	$4.670M	$4.924M
YoY Change	-3.54%	-28.51%	-18.15%
Gross Profit Margin	59.64%	75.91%	69.97%
Selling, General & Admin	$6.801M	$6.956M	$6.566M
YoY Change	-0.78%	-3.47%	26.83%
% of Gross Profit	148.92%	148.95%	133.35%
Research & Development	$2.818M	$2.893M	$2.447M
YoY Change	12.73%	6.48%	3.38%
% of Gross Profit	61.7%	61.95%	49.7%
Depreciation & Amortization	$104.0K	$94.00K	$100.0K
YoY Change	295.74%	255.39%	272.86%
% of Gross Profit	2.28%	2.01%	2.03%
Operating Expenses	$9.619M	$9.849M	$9.013M
YoY Change	2.83%	-0.75%	19.47%
Operating Profit	-$5.052M	-$5.179M	-$4.089M
YoY Change	9.35%	52.73%	167.58%
Interest Expense	$135.0K	$45.00K	$3.000K
YoY Change	10614.29%	-1850.97%	-170.09%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$4.917M	-$5.134M	-$4.086M
YoY Change	6.46%	324.16%	166.64%
Income Tax
% Of Pretax Income
Net Earnings	-$4.917M	-$5.134M	-$4.086M
YoY Change	6.46%	323.95%	166.64%
Net Earnings / Revenue	-64.22%	-83.45%	-58.06%
Basic Earnings Per Share	-$0.07	-$0.07	-$0.06
Diluted Earnings Per Share	-$0.07	-$0.07	-$53.85K
COMMON SHARES
Basic Shares Outstanding	74.79M shares	75.95M shares	75.88M shares
Diluted Shares Outstanding	76.10M shares	75.95M shares	75.88M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.94M	$33.50M	$35.10M
YoY Change	-23.12%	-20.35%	-17.33%
Cash & Equivalents	$30.94M	$33.50M	$35.10M
Short-Term Investments
Other Short-Term Assets	$1.903M	$1.609M	$2.496M
YoY Change	-55.11%	-63.28%	-23.47%
Inventory	$8.161M	$7.786M	$4.850M
Prepaid Expenses
Receivables	$5.077M	$3.748M	$4.693M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$46.08M	$46.64M	$47.13M
YoY Change	-13.73%	-15.56%	-16.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.409M	$3.260M	$8.904M
YoY Change	-54.89%	127.19%	369.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.108M	$1.224M	$1.391M
YoY Change	16.21%	83.81%	267.72%
Total Long-Term Assets	$9.996M	$10.04M	$10.30M
YoY Change	17.47%	377.76%	352.24%
TOTAL ASSETS
Total Short-Term Assets	$46.08M	$46.64M	$47.13M
Total Long-Term Assets	$9.996M	$10.04M	$10.30M
Total Assets	$56.08M	$56.68M	$57.43M
YoY Change	-9.44%	-1.15%	-2.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.941M	$4.244M	$2.892M
YoY Change	0.1%	277.52%	27.38%
Accrued Expenses	$3.211M	$2.126M	$2.063M
YoY Change	6.27%	-44.91%	-52.17%
Deferred Revenue	$8.043M	$6.959M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.55M	$13.66M	$11.49M
YoY Change	12.36%	1.65%	-31.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$168.0K	$202.0K	$8.032M
YoY Change	-97.88%	-89.11%	422.11%
Total Long-Term Liabilities	$168.0K	$202.0K	$8.032M
YoY Change			350.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.55M	$13.66M	$11.49M
Total Long-Term Liabilities	$168.0K	$202.0K	$8.032M
Total Liabilities	$22.72M	$21.15M	$19.52M
YoY Change	4.41%	38.33%	5.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$512.8M	-$507.9M
YoY Change
Common Stock	$75.00K	$75.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.77M	$29.94M	$32.32M
YoY Change
Total Liabilities & Shareholders Equity	$56.08M	$56.68M	$57.43M
YoY Change	-9.44%	-1.15%	-2.36%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.917M	-$5.134M	-$4.086M
YoY Change	6.46%	323.95%	166.64%
Depreciation, Depletion And Amortization	$104.0K	$94.00K	$100.0K
YoY Change	295.74%	255.39%	272.86%
Cash From Operating Activities	-$2.533M	-$1.137M	-$2.193M
YoY Change	308.96%	-3389.93%	618.62%
INVESTING ACTIVITIES
Capital Expenditures	-$205.0K	-$650.0K	-$1.154M
YoY Change	-76.91%	462.62%	3275.26%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$205.0K	-$650.0K	-$1.154M
YoY Change	-76.91%	462.62%	3275.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	48.00K	57.00K	54.00K
YoY Change	-64.11%	-52.52%	-80.84%
NET CHANGE
Cash From Operating Activities	-2.533M	-1.137M	-2.193M
Cash From Investing Activities	-205.0K	-650.0K	-1.154M
Cash From Financing Activities	48.00K	57.00K	54.00K
Net Change In Cash	-2.690M	-1.730M	-3.293M
YoY Change	95.84%	-4526.82%	5629.95%
FREE CASH FLOW
Cash From Operating Activities	-$2.533M	-$1.137M	-$2.193M
Capital Expenditures	-$205.0K	-$650.0K	-$1.154M
Free Cash Flow	-$2.328M	-$487.0K	-$1.039M
YoY Change	-966.88%	-424.47%	283.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	180000	usd
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Document Transition Report DocumentTransitionReport	false
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	STXS	Non Cash Interest NonCashInterest		usd
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	STXS	Increase Decrease Compensating Cash Arrangement IncreaseDecreaseCompensatingCashArrangement		usd
	STXS	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities		usd
	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q2	us-gaap	Sublease Income SubleaseIncome		usd
	us-gaap	Sublease Income SubleaseIncome		usd
	dei	Document Type DocumentType	10-Q
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74790074	shares
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33498000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38739000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	618000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	454000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	225000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001289340
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	dei	Entity File Number EntityFileNumber	001-36159
	dei	Entity Registrant Name EntityRegistrantName	STEREOTAXIS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3120386
	dei	Entity Address Address Line1 EntityAddressAddressLine1	710 North Tucker Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
	dei	Entity Address City Or Town EntityAddressCityOrTown	St. Louis
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	63101
	dei	City Area Code CityAreaCode	(314)
	dei	Local Phone Number LocalPhoneNumber	678-6100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	STXS
	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3748000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5406000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	7786000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4433000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	991000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2356000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	46641000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	51388000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3260000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2632000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1006000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	952000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5553000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5735000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	218000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	278000	usd
CY2022Q2	us-gaap	Assets Assets	56678000	usd
CY2021Q4	us-gaap	Assets Assets	60985000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4244000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4189000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2126000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2528000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6959000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6277000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	328000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	268000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13657000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13262000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1630000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2238000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5663000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5842000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	202000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	219000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	21152000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	21561000	usd
CY2022Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22386	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22387	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5584000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5584000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5610121	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5610121	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	6000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	6000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74686056	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74618240	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	537963000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	532641000	usd
CY2022Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2022Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-507896000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-498676000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	29942000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33840000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56678000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60985000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6152000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9051000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13189000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17674000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	1482000	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	2519000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3595000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5126000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	4670000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	6532000	usd
	us-gaap	Gross Profit GrossProfit	9594000	usd
	us-gaap	Gross Profit GrossProfit	12548000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2893000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2717000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5340000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5084000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3279000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3045000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6225000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5992000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3677000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4161000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7297000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6391000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	9849000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	9923000	usd
	us-gaap	Operating Expenses OperatingExpenses	18862000	usd
	us-gaap	Operating Expenses OperatingExpenses	17467000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5179000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3391000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9268000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4919000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	45000	usd
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	48000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-7000	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2183000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2183000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5134000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1211000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9220000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2743000	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	335000	usd
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	335000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	666000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	668000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5469000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1546000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9886000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3411000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75953916	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75547574	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75915864	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75362521	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75953916	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75547574	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75915864	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75362521	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	34771000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	87000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2785000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1211000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	33000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	36465000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	32322000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2698000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5134000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	30000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	29942000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	34624000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	340000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4156000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2743000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	61000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	27000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	36465000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33840000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	5211000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9220000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	66000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	29942000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9220000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2743000	usd
	us-gaap	Depreciation Depreciation	194000	usd
	us-gaap	Depreciation Depreciation	54000	usd
	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	63000	usd
	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	-26000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5211000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4156000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2183000	usd
	STXS	Non Cash Interest NonCashInterest	25000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1658000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1137000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3353000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	851000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1365000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	931000	usd
	STXS	Increase Decrease Compensating Cash Arrangement IncreaseDecreaseCompensatingCashArrangement	1000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-60000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1037000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-484000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-403000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-352000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	75000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4102000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-17000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	75000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3330000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-271000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1804000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	150000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1804000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-150000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	111000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	402000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	402000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5023000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40145000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43940000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35122000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43921000	usd
	STXS	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	116000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33498000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42054000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	618000	usd
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1484000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1006000	usd
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	383000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	35122000	usd
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	43921000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80E_eus-gaap--NatureOfOperations_zTTDC0FR9Hh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. <span id="xdx_827_zd5HzEqCtaha">Description of Business</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention. We design, manufacture and market robotic systems, instruments and information systems for the interventional laboratory. Our proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Direct control of the tip of an interventional device, in contrast to all manual hand-held devices that are controlled from their handle, can improve the precision, stability, reach and safety of these devices during procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiac ablation has become a well-accepted therapy for arrhythmias and a multi-billion-dollar medical device market with expectations for substantial long-term growth. We have shared our aspiration and a product strategy to expand the clinical focus of our technology to several additional endovascular indications including coronary, neuro, and peripheral interventions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial real-world evidence and clinical literature for Robotic Magnetic Navigation in electrophysiology. Hundreds of electrophysiologists at over one hundred hospitals globally have treated over 100,000 arrhythmia patients with our robotic technology. Clinical use of our technology has been documented in over 400 clinical publications. Robotic Magnetic Navigation is designed to enable physicians to complete more complex interventional procedures with greater success and safety by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied computer-controlled magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation. The more flexible atraumatic design of catheters driven using magnetic fields may reduce the risk of patient harm and other adverse events. Performing the procedure from a control cockpit enables physicians to complete procedures in a safe location protected from x-ray exposure, with greater ergonomics, and improved efficiency. We believe these benefits can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary products include the <i>Genesis RMN </i>System, the <i>Odyssey </i>Solution, and other related devices. We also offer to our customers the Stereotaxis Imaging Model S x-ray System and other accessory devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Genesis RMN System</i> is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation, efficient procedures, and reduced x-ray exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Odyssey Solution</i> consolidates lab information onto one large integrated display, enabling physicians to view and control all the key information in the operating room. This is designed to improve lab layout and procedure efficiency. The system also features a remote viewing and recording capability called <i>Odyssey Cinema,</i> which is an innovative solution that delivers synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation, and training.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have received regulatory clearances and registration approvals necessary for us to market the <i>Genesis RMN</i> System in the U.S. and Europe, and we are in the process of obtaining necessary registrations for extending our markets in other countries. The <i>Niobe</i> System, <i>Odyssey</i> Solution, <i>Cardiodrive</i>, and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the <i>Vdrive</i> and <i>Vdrive Duo</i> Systems with the <i>V-CAS</i>, <i>V-Loop </i>and <i>V-Sono </i>devices in the U.S., Canada and Europe. Stereotaxis Imaging Model S x-ray System is CE marked and FDA cleared.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue, and efforts are ongoing to ensure the availability of integrated systems and devices and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z1HTYK90b5b5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zp6BIUiG2FB2">Risks and Uncertainties</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The novel coronavirus COVID-19 (“COVID-19”) pandemic has resulted, and is likely to continue to result, in significant disruptions to the economy, as well as business and capital markets around the world. The full extent of the impact of the COVID-19 pandemic on our business, results of operations and financial condition will depend on numerous evolving factors that we may not be able to accurately predict.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the COVID-19 outbreak, we have experienced business disruptions, including travel restrictions on us and our third-party distributors, which have negatively affected our complex sales, marketing, installation, distribution and service network relating to our products and services. The COVID-19 pandemic may continue to negatively affect demand for both our systems and our disposable products by limiting the ability of our sales personnel to maintain their customary contacts with customers as governmental authorities institute prolonged quarantines, travel restrictions, and shelter-in-place orders, or as our customers impose limitations on contacts and in-person meetings that go beyond those imposed by governmental authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, many of our hospital customers, for whom the purchase of our system involves a significant capital purchase which may be part of a larger construction project at the customer site (typically the construction of a new building), may themselves be under economic pressures. This may cause delays or cancellations of current purchase orders and other commitments, and may exacerbate the long and variable sales and installation cycles for our robotic magnetic navigation systems. We may also experience significant reductions in demand for our disposable products as our healthcare customers (physicians and hospitals) continue to re-prioritize the treatment of patients and divert resources away from non-coronavirus areas, which we anticipate will lead to the performance of fewer procedures in which our disposable products are used. In addition, patients may consider foregoing or deferring procedures utilizing our products, even if physicians and hospitals are willing to perform them, which could also reduce demand for, and sales of, our disposable products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date of the filing of this Quarterly Report on Form 10-Q, we believe our manufacturing operations and supply chains have been manageably impacted, but we cannot guarantee that they will not be impacted more severely in the future. If our manufacturing operations or supply chains are materially interrupted, it may not be possible for us to timely manufacture relevant products at required levels, or at all. Changes in economic conditions and supply chain constraints could lead to higher inflation than previously experienced or expected, which could, in turn, lead to an increase in costs. We may be unable to raise the prices of our products sufficiently to keep up with the rate of inflation. A material reduction or interruption to any of our manufacturing processes or a substantial increase in costs would have a material adverse effect on our business, operating results, and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As governmental authorities around the world continue to institute prolonged mandatory closures, social distancing protocols and shelter-in-place orders, or as private parties on whom we rely to operate our business put in place their own protocols that go beyond those instituted by relevant governmental authorities, our ability to adequately staff and maintain our operations or further our product development could be negatively impacted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any disruption to the capital markets could negatively impact our ability to raise capital. If the capital markets are disrupted for an extended period of time and we need to raise additional capital, such capital may not be available on acceptable terms, or at all. Continued disruptions to the capital markets and other financing sources could also negatively impact our hospital customers’ ability to raise capital or otherwise obtain financing to fund their operations and capital projects. Such could result in delayed spending on current projects, a longer sales cycle for new projects where a large capital commitment is required, and decreased demand for our disposable products as well as an increased risk of customer defaults or delays in payments for our systems installation, service contracts and disposable products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We continue to evaluate and, where appropriate, take actions to reduce costs and spending across our organization. We will continue to actively monitor the situation and may take further actions that alter our business operations that may be required by federal, state, or local governmental authorities that may be implemented by our vendors, supplier or customers, or that we determine are in the best interests of our employees, customers, suppliers and stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p>
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5991000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	1600000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1400000	usd
CY2022Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1600000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1400000	usd
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6152000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9051000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13189000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17674000	usd
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14200000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	208000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	178000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8589000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8515000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1630000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2238000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6959000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6277000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4600000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000000.0	usd
CY2022Q2	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	200000	usd
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	200000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5134000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1211000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9220000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2743000	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	335000	usd
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	335000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	666000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	668000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5469000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1546000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9886000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3411000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75953916	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75547574	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75915864	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75362521	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	5554000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3642000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1405000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	133000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2981000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2823000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2154000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2165000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	7786000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4433000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	220000	usd
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	539000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	654000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1170000	usd
CY2022Q2	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	338000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1012000	usd
CY2022Q2	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	204000	usd
CY2021Q4	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	229000	usd
CY2022Q2	us-gaap	Deposits Assets DepositsAssets	584000	usd
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	1276000	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	83000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	117000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1209000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2634000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	218000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	278000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	991000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2356000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2126000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2528000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6554000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5843000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3294000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3211000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3260000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2632000	usd
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	800000	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5900000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5900000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y6M
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	226000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	583000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	451000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1165000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	14000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	20000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	31000	usd
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	247000	usd
	us-gaap	Sublease Income SubleaseIncome	493000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	236000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	350000	usd
	us-gaap	Lease Cost LeaseCost	471000	usd
	us-gaap	Lease Cost LeaseCost	703000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	413000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	871000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	891000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	912000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	933000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4986000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9006000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3015000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1213000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1516000	usd
CY2022Q2	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent	484000	usd
CY2021Q4	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent	484000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	209000	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	242000	usd
CY2022Q2	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	165000	usd
CY2021Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	177000	usd
CY2022Q2	STXS	Accrued Investigational Sites AccruedInvestigationalSites	102000	usd
CY2021Q4	STXS	Accrued Investigational Sites AccruedInvestigationalSites	123000	usd
CY2022Q2	STXS	Accrued Lease Deposit Payable AccruedLeaseDepositPayable	5000	usd
CY2021Q4	STXS	Accrued Lease Deposit Payable AccruedLeaseDepositPayable	124000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	150000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	81000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2328000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2747000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	202000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	219000	usd
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of common stock are entitled to one vote for each share held
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6200000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2818012000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	760500000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.80
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40523	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	152863000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.89
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3385126000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.26
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	199000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	125000	usd
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	115000	usd
CY2022Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	209000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	242000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	242000	usd
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	158000	usd
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	92000	usd

Files In Submission

Name	View Source	Status
0001493152-22-022008-index-headers.html	Edgar Link	pending
0001493152-22-022008-index.html	Edgar Link	pending
0001493152-22-022008.txt	Edgar Link	pending
0001493152-22-022008-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stxs-20220630.xsd	Edgar Link	pending
stxs-20220630_cal.xml	Edgar Link	unprocessable
stxs-20220630_def.xml	Edgar Link	unprocessable
stxs-20220630_pre.xml	Edgar Link	unprocessable
stxs-20220630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STXS
Stereotaxis, Inc. Stock $stxs

2022 Q3 Form 10-Q Financial Statement

#000149315222022008 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS Stereotaxis, Inc. Stock $stxs

2022 Q3 Form 10-Q Financial Statement

#000149315222022008 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS
Stereotaxis, Inc. Stock $stxs